Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00859456 · ClinicalTrials.gov registry record · Phase 2
Sunitinib in Certain Subtypes of Soft Tissue Sarcomas
A Phase 2 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00859456 is a Phase 2 study that was terminated before completion, run by Columbia University. The registered enrollment target is 10 participants.
The verdict
NCT00859456, a Phase 2 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the clinical response rate (complete response and partial response) in patients with metastatic, locally advanced, or locally recurrent vascular soft tissue sarcoma treated with sunitinib.
Interventions
- DRUG Sunitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-04 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00859456
The ClinicalTrials.gov registry entry for NCT00859456 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sunitinib is the first listed.
NCT00859456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00859456 about?
NCT00859456 is a clinical study titled "Sunitinib in Certain Subtypes of Soft Tissue Sarcomas". The purpose of this study is to determine the clinical response rate (complete response and partial response) in patients with metastatic, locally advanced, or locally recurrent vascular soft tissue sarcoma treated with sunitinib.
What is the current status of trial NCT00859456?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2007-04. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00859456?
The interventions under investigation include: Sunitinib (DRUG).
Who is sponsoring clinical trial NCT00859456?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.